NKTR · Nektar Therapeutics
$64.84
-3.42 (-5.01%)
At close · Jul 20
Market Cap
$2.19B
Shares
33.79M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$64.84
Open$67.34
Day$64.75–68.50
52W$21.02–109.00
Avg vol 30d1.1M
Short int6.9M · 20.4% float · 4.5d
Short vol64%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 8
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+4%
above
Price vs 50-day avg
−3%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
50%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+74%
trailing
YTD return
+53%
this year
Relative strength
+67%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $67 › 200d $62 — 50d above 200d
Institutional flow
Distributing
14 of 209 funds reported for Jun 30 · net -28.4K sh shares · +5 new
Insider flow
Distributing
Net -$42.1K over 90 days · 100% sells
Short interest
Rising
20.41% of float · ▲ +39.5% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
209 holders — near 1-yr high, broad support
Squeeze score
78
high risk · 0–100
Fundamentals
Revenue growth
+86%
Y/Y
EPS growth
−12%
Y/Y
Free cash flow
$-208.7M
Balance sheet
$15.1M
net cash
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+4%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
50%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $67 › 200d $62 — 50d above 200d
Institutional flow
Distributing
14 of 209 funds reported for Jun 30 · net -28.4K sh shares · +5 new
Insider flow
Distributing
Net -$42.1K over 90 days · 100% sells
Short interest
Rising
20.41% of float · ▲ +39.5% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
209 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $21
Now $65 · 50%
52-wk high $109
vs 200-day avg +4%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NKTR
this stock
Nektar Therapeutics
|
$2.19B | +53.4% | +86.0% | — | 20.4% |
|
ONC
BeOne Medicines Ltd.
|
$448.86B | +2.2% | +22179.2% | 913.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.95B | +6.0% | +46.2% | 28.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.47B | -12.8% | +20.8% | 16.4 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +0.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NKTR | -5.1% | +6.3% | +74.4% | -7.1% | +53.4% |
| SPY | -1.0% | -0.6% | +7.1% | -0.6% | +8.8% |
| vs SPY | -4.1% | +7.0% | +67.3% | -6.5% | +44.5% |
Key facts
CIK
906709
CUSIP
640268306
13F (30d)
13 filings
13 filers
Visit website
Investor relations